Revelation Biosciences Inc. (NASDAQ: REVB)
$1.86
-0.0100 ( -0.54% ) 363.8K
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
Market Data
Open
$1.86
Previous close
$1.87
Volume
363.8K
Market cap
$3.04M
Day range
$1.79 - $2.02
52 week range
$1.61 - $28.20
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 39 | Jan 30, 2024 |
8-k | 8K-related | 11 | Jan 23, 2024 |
8-k | 8K-related | 10 | Jan 22, 2024 |
def | Proxies and info statements | 3 | Dec 22, 2023 |
pre | Proxies and info statements | 1 | Dec 12, 2023 |
4 | Insider transactions | 1 | Dec 12, 2023 |
8-k | 8K-related | 15 | Nov 13, 2023 |
10-q | Quarterly Reports | 65 | Nov 09, 2023 |
4 | Insider transactions | 1 | Oct 18, 2023 |
4 | Insider transactions | 1 | Oct 17, 2023 |